Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization
Jie Zheng, Eleanor Wheeler, Maik Pietzner, Till F. M. Andlauer, Michelle S. Yau, April E. Hartley, Ben Michael Brumpton, Humaira Rasheed, John P. Kemp, Monika Frysz, Jamie W. Robinson, Sjur Reppe, Vid Prijatelj, Kaare Morten Gautvik, Louise Falk, , Jonathan H. Tobias
This study uses GWAS and Mendelian randomization to show that lower sclerostin levels increase risk of hypertension, type 2 diabetes, myocardial infarction, and atherogenic lipid profiles.
Arthritis & Rheumatology · Apr 25, 2023Peer-reviewedGenetic & Genomic Medicine